- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USFDA gives its nod to IOL chemicals and pharmaceuticals for a plant in Punjab
IOL chemicals and pharmaceuticals' Barnala based facility will export the drug ibuprofen after receiving an approval from USFDA on a site inspection of the plantIOL Chemicals and Pharmaceuticals, a Punjab based company has recently achieved a breakthrough in manufacturing its drug, ibuprofen, at a plant in Barnala. The company received the go-ahead after a site inspection conducted by the...
IOL chemicals and pharmaceuticals' Barnala based facility will export the drug ibuprofen after receiving an approval from USFDA on a site inspection of the plant
IOL Chemicals and Pharmaceuticals, a Punjab based company has recently achieved a breakthrough in manufacturing its drug, ibuprofen, at a plant in Barnala. The company received the go-ahead after a site inspection conducted by the US Food and Drug Administration.
With this development, IOL can now export a major chunk of ibuprofen to the US, thereby adding significantly to its export turnover. Ibuprofen is a drug used to treat minor aches and pains caused by common cold, headaches, toothaches, back or muscle aches.
The company has received establishment inspection report from the US Food and Drug Administration (USFDA) for the Barnala-based facility, IOLCP said in a filing to the BSE. "Post this approval, IOLCP will be able to garner additional business for its flagship Iburofen in world's largest pharma market--USA," it added.
The Barnala facility has already been approved by various regulatory agencies including Brazil's Anvisa, WHO and MOH, Japan, it added. Shares of IOLCP were trading at Rs 110.20 apiece on the BSE, up 18.75 percent from previous close (as reported by PTI).
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751